Effects of Atypical Protein Kinase C Inhibitor (DNDA) on Lung Cancer Proliferation and Migration by PKC-ι/FAK Ubiquitination Through the Cbl-b Pathway

PURPOSE: The options for treating lung cancers are limited, as diagnosis typically occurs during the late stages of the disease. There is a dire need to develop aPKC (atypical Protein Kinase C) inhibitors due to aPKC overexpression and contributions to lung cancer malignancies. In this study, we inv...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: BommaReddy, Raja Reddy, Patel, Rekha, Smalley, Tracess, Acevedo-Duncan, Mildred
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7047975/
https://ncbi.nlm.nih.gov/pubmed/32158232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S224866
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky